(Q33346522)

26 July 2017

title

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer (English)

1 reference

26 July 2017

1 reference

3

Mark A Rettenmaier

0 references

author name string

John V Brown

1

1 reference

26 July 2017

William A Peters

2

1 reference

26 July 2017

Cheri L Graham

4

1 reference

26 July 2017

Michael R Smith

5

1 reference

26 July 2017

Charles W Drescher

6

1 reference

26 July 2017

John Paul Micha

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

88

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

136-140

1 reference

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Letter: Creatinine clearance: bedside estimate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900021-5

7 January 2021

10.1016/S0090-8258(02)00021-5

Identifiers

DOI

1 reference

26 July 2017

1 reference